Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent purified inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Cantacuzino
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
The trivalent purified inactivated influenza vaccine is a biological vaccine developed by the Cantacuzino National Institute of Research and Development for Microbiology and Immunology (INCDMI Cantacuzino) in Romania. It is an inactivated (killed-virus) vaccine administered parenterally to prevent seasonal influenza. The vaccine contains purified hemagglutinin (HA) surface antigens from three influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and one influenza B strain, updated annually based on World Health Organization (WHO) recommendations. It has been evaluated in Phase 3 clinical trials in Romania to assess safety, reactogenicity, and immunogenicity in both healthy adults and elderly populations.
- Other names
- Cantacuzino seasonal trivalent inactivated influenza vaccineVaccin gripal trivalent purificat şi inactivat
02
Targets
HA (Influenza A virus hemagglutinin (H1N1))HA (Hemagglutinin)HA (Influenza A virus hemagglutinin (H3N2))
Beyond the preview
Go deeper on trivalent purified inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent purified inactivated influenza vaccine.